The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Use at an assay dependent concentration.
60 min at RT. No protease pre-treatment. Blocking of endogenous enzymes is recommended, depending on kind of secondary reagents The volume is sufficient for at least 50 immunohistochemical tests (100 µl working solution / test).
FunctionGFAP, a class-III intermediate filament, is a cell-specific marker that, during the development of the central nervous system, distinguishes astrocytes from other glial cells.
Tissue specificityExpressed in cells lacking fibronectin.
Involvement in diseaseDefects in GFAP are a cause of Alexander disease (ALEXD) [MIM:203450]. Alexander disease is a rare disorder of the central nervous system. It is a progressive leukoencephalopathy whose hallmark is the widespread accumulation of Rosenthal fibers which are cytoplasmic inclusions in astrocytes. The most common form affects infants and young children, and is characterized by progressive failure of central myelination, usually leading to death usually within the first decade. Infants with Alexander disease develop a leukoencephalopathy with macrocephaly, seizures, and psychomotor retardation. Patients with juvenile or adult forms typically experience ataxia, bulbar signs and spasticity, and a more slowly progressive course.
Sequence similaritiesBelongs to the intermediate filament family.
Post-translational modificationsPhosphorylated by PKN1.
Cellular localizationCytoplasm. Associated with intermediate filaments.
References for Anti-GFAP antibody [MIG-G2], prediluted (ab51838)
This product has been referenced in:
Shields DC et al. Increased calpain expression in activated glial and inflammatory cells in experimental allergic encephalomyelitis. Proc Natl Acad Sci U S A95:5768-72 (1998).
Read more (PubMed: 9576959) »